The HCPLive Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.
June 4th 2023
A new-user, active comparator cohort study from EULAR 2023 suggests use of SGLT2 inhibitors could lower risk of recurrent gout flares in people with type 2 diabetes and gout compared to use of DPP-4 inhibitors.
Achieving Remission with Methotrexate or TNFi Linked to Lower CV Risk in Rheumatoid Arthritis
May 31st 2023An analysis of patient data from Sweden and Norway detail the impact of achieving remission with methotrexate or TNF inhibitors on risk of acute coronary syndrome in patients with rheumatoid arthritis.
BE VITAL: Bimekizumab Helps Control, Attenuate Disease Activity in Psoriatic Arthritis
May 31st 2023Data from the BE VITAL OLE study, which included patients from the BE COMPLETE and BE OPTIMAL studies, suggests the benefits of bimekizumab in patients with psoriatic arthritis with inadequate response or intolerance to TNF inhibitors were sustained for up to 52 weeis.
Janssen Develops Programs to Support Health Equity in Psoriatic Disease
The disparities compelled them to launch Determi-Nation, which utilizes healthcare providers, advocates, and patients within the psoriatic disease community to co-create solutions that address the observed inequities.
Study Offers Overview of Features, Outcomes, Treatment for Immune-Mediated Necrotizing Myopathy
May 8th 2023A study leveraging DoD data provides a comprehensive overview of clinical features, treatment choices, and outcomes of patients with immune mediated necrotizing myopathy relative to those of patients with other idiopathy inflammatory myopathies.
RAIL Score Provides Useful, Noninvasive Biomarker for Renal Disease Activity
May 7th 2023An analysis of data obtained from urine samples in the MUSE and TULIP-1 trial sheds new light on the clinical utility of the RAIL score for identifying disease activity and treatment responders in SLE patients with and without lupus nephritis, respectively
Study Underlines Potential of IL-6 Inhibitors for Polymyalgia Rheumatica
May 7th 2023An analysis of Medcare claims data offers clinicians an overview or the effectiveness of sarilumab and tocilizumab in second- and third-line polymyalgia rheumatica treatments relative to conventional immunomodulators, such as methotrexate or azathioprine.
Vitamin D Levels Can Influence Risk of Miscarriage, Premature Delivery in Women with Lupus
May 6th 2023An analysis of more than 250 pregnancies among women with SLE from the Hopkins Lupus Cohort provides insight into risk of adverse pregnancy outcomes based on serum 25-hydroxy vitamin D levels using real-world data.
Dermatomyositis, Polymyositis Linked to Doubling in Risk of Mortality in Heart Failure Patients
May 6th 2023An analysis of the National Inpatient Sample offers a deep dive into the risk of adverse outcomes associated with presence of polymyositis or dermatomyositis among patients with congestive heart failure.
Renal Biopsy Data Supports Long-Term Voclosporin Use for Lupus Nephritis
May 5th 2023Data from an analysis of kidney biopsies from the AURORA 2 trial presented at CCR East 2023 offer new insight into the long-term histological impact of voclosporin use on renal function in patients with lupus nephritis.